As longtime CMO exits, Karyopharm taps Big Pharma vets to steer cancer drug franchise
As Richard Paulson continues to make a case for the Xpovio franchise, he will be surrounding himself with a new clinical team at Karyopharm.
The biotech revealed Tuesday that executive vice president and chief medical officer Jatin Shah departs for “other professional opportunities.” While CEO Paulson looks for Shah’s replacement, he has recruited two Big Pharma vets to take up key posts on the team: Patricia Judson, who led women’s oncology at both GlaxoSmithKline and AstraZeneca, will become SVP of medical strategy; and Stuart Poulton, formerly of AbbVie, Amgen and Eli Lilly, has been appointed SVP of strategy and portfolio management.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.